65302-062-05 : NDC 2026 Code

65302-062-05 : Tafluprost ( Tafluprost )

Additionally :

You can get information about “65302-062-05” NDC code in 65302-062-05 in HTML format

HTML | 65302-062-05 in TXT (Plain Text) format

TXT | 65302-062-05 in PDF (Portable Document Format)

PDF | 65302-062-05 in XML format

XML formats.

NDC Code : 65302-062-05 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "65302-062-05",
    "PackageDescription": "6 POUCH in 1 CARTON (65302-062-05)  &gt; 5 AMPULE in 1 POUCH &gt; .3 mL in 1 AMPULE",
    "NDC11Code": "65302-0062-05",
    "ProductNDC": "65302-062",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Tafluprost",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Tafluprost",
    "DosageFormName": "SOLUTION",
    "RouteName": "OPHTHALMIC",
    "StartMarketingDate": "20221205",
    "EndMarketingDate": null,
    "MarketingCategoryName": "ANDA",
    "ApplicationNumber": "ANDA209040",
    "LabelerName": "The Ritedose Corporation",
    "SubstanceName": "TAFLUPROST",
    "StrengthNumber": ".0045",
    "StrengthUnit": "mg/.3mL",
    "Pharm_Classes": "Increased Prostaglandin Activity [PE], Prostaglandin Analog [EPC], Prostaglandin Receptor Agonists [MoA], Prostaglandins [CS]",
    "DEASchedule": null,
    "Status": "Deprecated",
    "LastUpdate": "2024-01-02",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20231231",
    "StartMarketingDatePackage": "20221205",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}